New active leads for tuberculosis booster drugs by structure-based drug discovery.

about

Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.

P2860

Q50028742-88A6A516-7557-48E4-A0A3-E81C1D605FDA

P2860

New active leads for tuberculosis booster drugs by structure-based drug discovery.

Item

http://www.wikidata.org/entity/Q47813934

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

New active leads for tuberculosis booster drugs by structure-based drug discovery.

@en

New active leads for tuberculosis booster drugs by structure-based drug discovery.

@nl

type

Item

label

New active leads for tuberculosis booster drugs by structure-based drug discovery.

@en

New active leads for tuberculosis booster drugs by structure-based drug discovery.

@nl

prefLabel

New active leads for tuberculosis booster drugs by structure-based drug discovery.

@en

New active leads for tuberculosis booster drugs by structure-based drug discovery.

@nl

P1476

New active leads for tuberculosis booster drugs by structure-based drug discovery.

@en

P2093

Adrien Herledan

http://www.w3.org/2001/XMLSchema#string

Jason C Cole

http://www.w3.org/2001/XMLSchema#string

John W Liebeschuetz

http://www.w3.org/2001/XMLSchema#string

Nicolas Willand

http://www.w3.org/2001/XMLSchema#string

P2860

KNIME-CDK: Workflow-driven cheminformatics

Mycobacterium tuberculosis: success through dormancy

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

Exploring drug target flexibility using in situ click chemistry: application to a mycobacterial transcriptional regulator

Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis

Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches

Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis

Diamond: shedding light on structure-based drug discovery

EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator

P304

10245-10255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1039/C7OB00910K

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29182187

http://www.w3.org/2001/XMLSchema#string

New active leads for tuberculosis booster drugs by structure-based drug discovery.

about

P2860

P2860

New active leads for tuberculosis booster drugs by structure-based drug discovery.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698